Durvalumab Tolerability in Non–Small Cell Lung Cancer

preview_player
Показать описание
Discussing tolerability and adverse events of durvalumab. Understanding that early recognition and intervention is key to avoiding negative outcomes.

  1. Targeted Oncology
  2. targeted oncology
  3. oncology
  4. cancer
Рекомендации по теме
Durvalumab Tolerability in 0:04:25

Durvalumab Tolerability in Non–Small Cell Lung Cancer

Stage III NSCLC: 0:06:06

Stage III NSCLC: When to Start Durvalumab

Dr. Simon on 0:01:20

Dr. Simon on Durvalumab for Patients With Lung Cancer

SAFIR 02: Durvalumab 0:02:12

SAFIR 02: Durvalumab compared to maintenance chemotherapy for metastatic non-small cell lung cancer

The Use of 0:03:07

The Use of Durvalumab in Locally Advanced NSCLC

Results for Durvalumab 0:01:37

Results for Durvalumab in the Second-Line Treatment of NSCLC

A Study of 0:01:18

A Study of Chemotherapy With Durvalumab and Tremelimumab in NSCLC

Dr. Bazhenova on 0:01:08

Dr. Bazhenova on the PACIFIC Trial With Durvalumab in NSCLC

Durvalumab: the new 0:01:24

Durvalumab: the new standard of care for NSCLC?

Durvalumab as a 0:01:28

Durvalumab as a Consolidation Therapy for Locally Advanced NSCLC

Results from the 0:03:39

Results from the PACIFIC study: durvalumab with chemoradiation for the treatment of NSCLC

What is durvalumab’s 0:03:39

What is durvalumab’s future as a treatment option in lung cancer?

Durvalumab Consolidation in 0:05:28

Durvalumab Consolidation in NSCLC: The PACIFIC Trial

Tips for Managing 0:05:14

Tips for Managing NSCLC Patients on Durvalumab Therapy

Implications for Using 0:06:50

Implications for Using Durvalumab in Stage 3 NSCLC

Tremelimumab and durvalumab 0:02:03

Tremelimumab and durvalumab therapy in lung cancer

HUDSON: Durvalumab combination 0:02:53

HUDSON: Durvalumab combination therapies to overcome PD-L1 blockade resistance in advanced NSCLC

PACIFIC 6: durvalumab 0:03:25

PACIFIC 6: durvalumab after sCRT in patients with NSCLC

Phase 1b trial 0:03:16

Phase 1b trial of durvalumab plus tremelimumab for advanced non-small cell lung cancer

Dr. Langer on 0:02:10

Dr. Langer on the Benefit of Durvalumab in Stage III NSCLC

Case 1: Immunotherapy 0:06:47

Case 1: Immunotherapy in Locally Advanced NSCLC

Dr. Patel on 0:00:57

Dr. Patel on the FDA Approval of Durvalumab in NSCLC

Double immunotherapy with 0:00:43

Double immunotherapy with durvalumab and tremelimumab versus quadruple therapy in NSCLC

Effectively Managing Treatment 0:05:13

Effectively Managing Treatment With Durvalumab